Gyre Therapeutics, Inc. Increase (Decrease) in Other Noncurrent Liabilities
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Other Noncurrent Liabilities of -$47.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-03-13
- Gyre Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-12-31 was $26.00K, a 96.16% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-09-30 was -$22.00K, a 150.00% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-06-30 was $23.00K.
- Gyre Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-03-31 was -$4.00K.
- Gyre Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2025 was -$47.00K, a 304.35% decline from fiscal 2024.
- Gyre Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2024 was $23.00K.
- Gyre Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2023 was -$102.00K.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$47.00K 10-K · filed 2026-03-13 | |||
| 2024-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $4.00K derived: sum of 2 quarters · filed 2026-03-13 | $27.00K derived: sum of 3 quarters · filed 2026-03-13 | $23.00K 10-K · filed 2026-03-13 |
| 2024-09-30 | -$22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.00K derived: sum of 2 quarters · filed 2024-11-13 | -$3.00K 10-Q · filed 2024-11-13 | $674.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2024-06-30 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $19.00K 10-Q · filed 2024-08-13 | $696.00K derived: sum of 3 quarters · filed 2025-03-17 | $740.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2024-03-31 | -$4.00K 10-Q · filed 2024-05-13 | $673.00K derived: sum of 2 quarters · filed 2025-03-17 | $717.00K derived: sum of 3 quarters · filed 2025-03-17 | $702.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-12-31 | $677.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $721.00K derived: sum of 2 quarters · filed 2025-03-17 | $706.00K derived: sum of 3 quarters · filed 2025-03-17 | -$102.00K 10-K · filed 2025-03-17 |
| 2023-09-30 | $44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $29.00K derived: sum of 2 quarters · filed 2024-11-13 | -$779.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$823.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$808.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |